IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed May 15, 2023 · 10-Q · 45 days after period end · 0000950170-23-022241
| Metric | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|
| Net Income | -$12.25M | -$21.64M | -$23.09M | -$17.18M |
| EPS Diluted | -$0.34 | -$0.72 | -$0.78 | -$0.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end
